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Aims Staphylococcus aureus infective endocarditis (IE) is a critical medical condition associated with a high morbidity and
mortality. In the present study, we prospectively evaluated the importance of screening with echocardiography in
an unselected S. aureus bacteraemia (SAB) population.
Methods
and results
From 1 January 2009 to 31 August 2010, a total of 244 patients with SAB at six Danish hospitals underwent screening
echocardiography. The inclusion rate was 73% of all eligible patients (n ¼ 336), and 53 of the 244 included patients
(22%; 95% CI: 17–27%) were diagnosed with definite IE. In patients with native heart valves the prevalence was 19%
(95% CI: 14–25%) compared with 38% (95% CI: 20–55%) in patients with prosthetic heart valves and/or cardiac
rhythm management devices (P ¼ 0.02). No difference was found between Main Regional Hospitals and Tertiary
Cardiac Hospitals, 20 vs. 23%, respectively (NS). The prevalence of IE in high-risk patients with one or more predis-
posing condition or clinical evidence of IE were significantly higher compared with low-risk patients with no additional
risk factors (38 vs. 5%; P, 0.001). IE was associated with a higher 6 months mortality, 14(26%) vs. 28(15%) in SAB
patients without IE, respectively (P, 0.05).
Conclusion SAB patients carry a high risk for development of IE, which is associated with a worse prognosis compared with
uncomplicated SAB. The presenting symptoms and clinical findings associated with IE are often non-specific and
echocardiography should always be considered as part of the initial evaluation of SAB patients.
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Introduction
Staphylococcus aureus bacteraemia (SAB) is a serious, common
medical condition that is often associated with metastatic infec-
tions.1 –3 One of the most dreaded complications of SAB is
infective endocarditis (IE), which has been reported to occur in
6–32% of these patients.4 –8
During the past decades, medical advances have caused a shift in
the underlying conditions predisposing to IE. As a result the com-
plexity of IE has increased with more device infections,
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comorbidity, health-care related infections and resistance to an
increasing number of antibiotics.9 –13 Because of these changes
the prevalence of S. aureus IE is also increasing, and S. aureus is
now the leading cause of IE in many regions of the industrialized
world.14–16 Despite recent advances in both diagnosis and treat-
ment of IE, S. aureus IE continues to be associated with a high
morbidity and mortality.14,17
The diagnosis of IE in SAB patients is primarily based on echo-
cardiography as the clinical findings associated with IE often are
unspecific.15,18 Thus, most international guidelines regarding IE rec-
ommend that all SAB patients should be evaluated by transesopha-
geal echocardiography (TEE) as these patients constitute a
high-risk population.19 The sensitivity of TEE in patients with sus-
pected IE is reported to be almost 100%. For this reason, TEE is
often preferred in patients with high initial risk of IE. By contrast,
transthoracic echocardiography (TTE) is of more limited value in
these patients due to a poorer diagnostic sensitivity of 50–
80%.20 –24 Despite these recommendations echocardiography is
not routinely used in cases of presumed uncomplicated SAB in
many institutions.8,25 This is a concern as this practice may lead
to unrecognized cases of IE and treatment failure.
The aim of this prospective multicentre study was to clarify the
value of echocardiographic screening for IE in an unselected SAB
population. To achieve this we wanted (i) to determine the preva-
lence of IE in SAB patients and (ii) to identify SAB patients with
high initial risk of IE.
Methods
Study population
In a prospective observational study, SAB patients admitted at six
Danish hospitals in the period 1 January 2009 to 31 August 2010,
were screened with echocardiography in accordance with national
guidelines on IE (www.cardio.dk). The hospitals enrolling patients in
the current study included both Main Regional Hospitals and Tertiary
Cardiac Hospitals. Clinical data and echocardiographic findings were
prospectively obtained for all patients who fulfilled the inclusion cri-
teria and were enrolled in the study.
A total of 427 patients were diagnosed with one or more blood
culture positive for S. aureus and clinical signs of infection in the
study period. Ninety-one patients were excluded due to: age ,18
years (n ¼ 17), neutropenia (white blood count ,1.0 × 109 cells
per litre) (n ¼ 21), death before the echocardiography could be per-
formed (n ¼ 30), discharged or transferred to another hospital (n ¼
23). Of the remaining 336 eligible patients, echocardiography was per-
formed in 244 (73%) of the cases (Figure 1).
SAB patients who fulfilled the inclusion criteria in the study period
were examined with both TEE and TTE at the discretion of the phys-
ician, but TEE was directly encouraged in all cases. The risk of compli-
cations associated with TEE is usually low but can be higher in very sick
patients who are unable to cooperate to the procedure. As these
patients are of particular interest TTE was performed if the patient
was not suited for TEE. In these cases, if high-risk echocardiographic
features were present on the initial TTE, an additional TEE was per-
formed later on or using general anaesthesia. However, if the TEE
was not performed the patient was still included in the study and
was categorized based on the TTE findings. All echocardiographies
were performed by experienced echocardiographers and the final
diagnosis determined by a local cardiac specialist appointed by the
steering committee.
Data on primary focus of the infection, surgical procedure prior to
the infection, predisposing cardiac conditions, symptoms, clinical
findings normally associated with IE, mode of acquisition, e.g. com-
munity acquired, nosocomial and non-nosocomial health-care
related infection, treatment and echocardiographic findings were col-
lected on case-report forms and prospectively entered into a data-
base at the main coordination centre (Copenhagen University
Hospital, Gentofte).
To ensure that no cases of IE were overlooked, especially in the
group of SAB patients where TEE was not performed, patients were
followed up for a minimum of 30 days after the index admission.
This follow-up also included eligible patients not enrolled in the
study. To do this we used the Danish National Patient Register,
which holds information about all admissions to Danish Hospitals,
including diagnose codes. Furthermore, information on 30 day and 6
month all-cause mortality was obtained using each patient’s civil regis-
tration number. Centralized registration of death based on the individ-
ual civil registration number is unique for Scandinavia and guarantees a
100% follow-up.
Based on sample size calculation a sample of 198 patients with SAB
would be required to obtain a 95% confidence interval of +5%
around an endocarditis prevalence estimate of 15%.
The present study was conducted in accordance with the regu-
lations by the Ethics Committee and the study was approved by the
Danish Data Protection Agency ( j.nr. 2007-58-0015).
Definitions
The infection was characterized by the source and acquisition. A
focus was considered to be primary if signs of infection were
present prior or simultaneous with bacteraemia. SAB was divided
into three groups according to the mode of acquisition; (i) commu-
nity acquired: if the first blood culture was obtained ,48 h after
admission, (ii) nosocomial: if the first blood culture was obtained
Figure 1 Patient selection.
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.48 h after hospitalization, (iii) non-nosocomial health-care related:
if the first blood culture was obtained ,48 h after admission and
one of the following criteria was met (i) home-based nursing or
intravenous therapy, e.g. haemodialysis or intravenous chemotherapy
,0 days before the SAB occurred (ii) admitted to an acute care
facility ,90 days before SAB occurred, and (iii) resident in a
nursing home or long-term care facility.19
The diagnosis of IE was in accordance with the modified Duke cri-
teria and only cases of definite IE were regarded as IE in this study.26
Echocardiographic findings consistent with IE included (i) an oscillating
intracardiac mass or vegetation attached to a heart valve or other
endocardial structures, including the endocardium and the ascending
aorta or implanted intracardiac material, (ii) perivalvular involvement
including abscesses, pseudoaneurisms and fistulation, (iii) prosthetic
valve dehiscence and (iv) new valvular regurgitation due to perforation
or destruction of the heart valve.26,27
The patients were divided into low- and high-risk groups based on
predisposing cardiac conditions and clinical findings. SAB patients
were regarded as having a high initial risk of IE if one or more of
the following were present: prosthetic heart valve, cardiac rhythm
management device (CRMD), previous IE, known heart valve
disease, intravenous drug abuse, heart murmur, embolic events,
heart failure, vascular or immunologic phenomena and unknown
source of SAB.19,28
Clinical findings reported in this study were based on the clinical
examination done by the treating physicians and no additional examin-
ations were performed by the investigators. In addition, only predis-
posing cardiac conditions known to the patient or treating physician
before echocardiography was registered as such, whereas echocardio-
graphic findings were registered separately.
Statistical analysis
Descriptive data were expressed as mean+ standard deviation (SD)
or mean (95% confidence interval). When a normal distribution was
uncertain the median and range was given. The statistical evaluation
of two groups was done with a two-sample t-test if the data were
normally distributed. When the distribution was skewed, the Mann–
Whitney test was used. Fisher’s exact test and X2 test were used to
evaluate binomial data.
Descriptive univariate analysis and multivariate logistic regression
analysis were carried out and used to assess the predictive value of
risk factors on IE. Only variables with a significant association with IE
in the univariate analysis were included in the multivariate analysis.
Differences in survival were estimated using log rank test. A 5% two-
sided significance level was used. Statistical calculations were pre-
formed with SPSS Inc. (IL, USA), version 18.0.
Results
Prevalence and echocardiographic
findings
Of the 244 patients included in this study, 84 (34%) were admitted
to a Main Regional Hospital, whereas 160 (66%) were admitted
to a Tertiary Cardiac Hospital. Overall 53 patients (22%; 95% CI:
17–27%) were diagnosed with definite IE in accordance with the
Duke criteria and all cases were verified with echocardiography.
The prevalence of IE was 19% (95% CI: 14–25%) in patients
with native valves and 38% (95% CI: 20–55%) in patients with
prosthetic valves and/or CRMD (P ¼ 0.02). Importantly, the
prevalence of IE among SAB patients were comparable between
Main Regional Hospitals (20%) and Tertiary Cardiac Hospitals
(23%) (NS). When the 92 eligible patients not examined with
echocardiography were included in the analysis the prevalence
was still as high as 16%.
In the majority of the SAB patients, 152 (62%) were evaluated
with TEE with or without additional TTE, whereas the rest of
the patients were evaluated with TTE. In eight of the patients
with IE, the diagnosis was confirmed only by TTE as further exam-
ination with TEE was not feasible and the patients were not candi-
dates for cardiac surgery. The mitral valves were most commonly
affected (34%), followed by aortic valves (28%). The presence of
valvular vegetations was the most common echocardiographic
finding associated with IE (Table 1).
In order to reduce the risk of missing the IE diagnosis, especially
in the group of SAB patients only evaluated with TTE, patients
were followed up for 30 days after the index admission. According
to this follow-up no patients initially regarded as not having IE were
readmitted within the follow-up period with the IE diagnosis.
Risk factors
Patient characteristics of SAB patients with and without definite IE
were compared in order to identify risk factors associated with IE.
The two groups were comparable with regard to age and gender.
Patients with unknown source of SAB [20 (38%) vs. 31 (16%); P ¼
0.001] and community-acquired infection [30 (57%) vs. 64 (34%);
P ¼ 0.002] were more likely to have IE. As expected, IE patients
were significantly more likely to have one or more predisposing
conditions, e.g. intravenous drug abuse, pre-existing heart valve
disease, prosthetic heart valve or CRMD [22 (42%) vs. 32 (17%);
P, 0.001) (Table 2).
While SAB patients with and without IE exhibited no significant
differences in presenting symptoms reported by the patients, IE
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Echocardiographic findings in Staphylococcus
aureus bacteraemia patients diagnosed with definite IE
No. (%)
Location of infection
Aortic 15 (28)
Mitral 18 (34)
Tricuspid 4 (8)
Dual 8 (15)
Dual and CRMD 1 (2)
CRMD 6 (11)
Atrial septal defect 1 (2)
Echocardiographic finding
Vegetation 49 (93)
Pseudoaneurysm 3 (6)
Abscess 1 (2)
Dehiscence of a prosthetic valve 2 (4)
Perforation 6 (11)
CRMD, cardiac rhythm management devices.
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patients were significantly more likely to exhibit heart murmurs,
emboli, and vascular or immunologic phenomena (Table 3).
Variables significantly associated with IE (e.g. unknown source of
SAB, community acquired infection, presence of one or more pre-
disposing conditions, heart murmur, vascular, or immunologic
phenomena and embolic events) were included in a multivariate
logistic regression analysis. Embolic events odds ratio (OR)
5.73 (95% CI: 1.66–19.79; P ¼ 0.006), one or more predisposing
conditions, e.g. intravenous drug abuse, pre-existing valvular dis-
order, prosthetic valves, or CRMD, OR: 3.09 (95% CI: 1.42–6.74;
P ¼ 0.004), unknown source of SAB, OR: 2.79 (95% CI: 1.28–6.10;
P ¼ 0.01), and heart murmur, OR: 2.79 (95% CI: 1.28–6.06 P ¼
0.01) were all found to be independently associated with an
increased risk of IE. When the patients were divided as having a
low risk (n ¼ 120) and high risk (n ¼ 124) of IE based on predis-
posing conditions and clinical findings as previously defined, we
were able to predict 87% of the IE cases, whereas the risk
factors failed to identify six ‘low-risk’ IE patients. Both TTE and
TEE were performed in these six patients. In four of them IE
was identified by both TTE and TEE, whereas TTE failed to identify
IE in two. Overall the prevalence of IE in low-risk SAB patients was
5% compared with 38% in high-risk SAB patients (P, 0.001).
Treatment and mortality
The duration of antibiotic treatment was longer for SAB patients
diagnosed with IE. Seventeen (32%) of these patients were
treated with an invasive procedure, as 6 patients were treated
with extraction of an infected device and 11 patients received
cardiac surgery. SAB was associated with a poor outcome with a
30 day overall mortality of 9%. Even though not significant there
was a trend towards a higher 30 day mortality in patients with IE
vs. without IE [7 (13%) vs. 14 (7%); (NS)]. This difference
became significant after 6 month as the 180 days mortality of
S. aureus IE patients was 14 (26%) compared with 28 (15%) in
SAB patients without IE (P, 0.05).
Eligible patients not included
To minimize the confounding effect of selection bias related to phys-
icians referring high-risk SAB patients for echocardiography, we also
evaluated the 92 patients with SAB not referred for echocardiogra-
phy. The mean age in this group was 62 (17) years and 67% were
males. Two patients were lost from follow-up as they were not
Danish citizens. Four (4%) out of 90 patients experienced recurring
SAB infections, 2 of these within 30 days after discharge. However,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Classification of infection and predisposing factors in Staphylococcus aureus bacteraemia patients with and
without definite IE
SAB patients without
IE (n 5 191), No. (%)
SAB patients with
IE (n5 53), No. (%)
P-value
Age (years), mean (SD) 65 (16) 64 (16) 0.6
Male gender 121 (63) 33 (62) 0.9
Primary foci
Intravenous catheters 39 (20) 5 (9) 0.07
Dialysis catheter 22 (12) 6 (11) 1.0
Gastro-intestinal tract 3 (2) – 1.0
Urinary tract 8 (4) 6 (11) 0.09
Teeth 2 (1) – 1.0
Pneumonia 18 (9) 3 (6) 0.6
Osteomyelitis 21 (11) 1 (2) 0.05
Unknown 31 (16) 20 (38) 0.001
Others 47 (25) 12 (23) 0.6
Acquisition
Community acquired 64 (34) 30 (57) 0.002
Hospital acquired 69 (36) 11 (21) 0.04
Health-care related non-nosocomial 58 (30) 12 (23) 0.3
Predisposing conditions
≥1 predisposing conditionsa 32 (17) 22 (42) ,0.001
Intravenous drug abuse 2 (1) 2 (4) 0.2
Previous IE 2 (1) 2 (4) 0.2
Native heart valve disease 8 (4) 10 (19) 0.001
Prosthetic valve 14 (7) 6 (11) 0.4
CRMD 7 (4) 7 (13) 0.02
Invasive procedure within 3 months 67 (35) 11 (21) 0.05
Immunodeficiency 24 (13) 3 (6) 0.2
IE, infective endocarditis; CRMD, cardiac rhythm management device.
aDefined as intravenous drug abuse, previous IE, native heart valve disease, prosthetic heart valve, CRMD.
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during this 30 day follow-up period, no patients readmitted from this
patient group were diagnosed with IE. Mortality in the group was high
both at 30 days (19%) and at 6 months (31%).
Discussion
In the present study, we found a high prevalence (22%) of IE in SAB
patients when systematic screening with echocardiography was
applied. This finding is of clinical importance, as S. aureus IE is a
potentially lethal infection that is often unsuspected on clinical
grounds alone.7,18,21,29,30 Thus, it is vital that patients with
S. aureus IE are diagnosed early in the course of the disease in
order to optimize clinical outcome.
One potential strategy for the early and accurate identification
of S. aureus IE is to perform screening echocardiography on all
patients with SAB.22 One of the first studies supporting a
general screening of SAB patients with echocardiography was a
study by Fowler et al.7, including 103 SAB patients who underwent
both TTE and TEE. In this study, 25% of the patients were diag-
nosed with IE according to the Duke criteria, whereas clinical evi-
dence of IE was present in only 7% of the patients. Based on these
findings, the authors concluded that it was impossible, based on
clinical findings and predisposing heart valve disease alone, to dis-
tinguish between SAB patients with and without IE and that TEE
should be considered in all patients with SAB.7 Although well con-
ducted, the study by Fowler et al. was associated with several limit-
ations, including (i) limited sample size, (ii) single-centre design; and
(iii) potential for ascertainment bias associated with its observa-
tional methodology. Subsequent retrospective studies using echo-
cardiography to evaluate the prevalence of IE in SAB patients have
found similar estimates, but were similarly limited by study
design.4,28,31 Thus, based on existing evidence it has not been poss-
ible to reach definite conclusions regarding the value of general
screening with echocardiography in patients with SAB.
In the present study, we used a large, multicentre, prospective
observational study of consecutive SAB patients to overcome
these limitations and make an observation. First, our study vali-
dated the high rate of IE reported in the Fowler study, with
reported prevalence rates virtually identical to those from the
earlier investigation (25 vs. 22%). Taken together, our findings
underscore that patients with SAB constitute a high-risk population
and as such should be examined with echocardiography. The
second key finding of this study was to identify a high-risk SAB
population based on predisposing conditions and clinical findings.
The likelihood of IE in SAB patients with a high initial risk of IE
was six times higher compared with low-risk patients with no
additional risk factors or stigmata of IE. This finding is in contrast
with that encountered by Fowler et al., and may be due in part
to time after onset of SAB to echocardiography, referral patterns,
and difference in patient demographics (for example, the high rate
of haemodialysis in the US vs. Danish patients). While the ability to
define ‘high-risk’ patients with SAB is highly relevant, it is important
to emphasize that all of the patients with SAB in our study were at
risk for IE. In the present study, over half of our patients with con-
firmed S. aureus IE had no documented cardiac murmur, three-
quarters of IE patients had no clinically detected embolic events,
and almost 90% had no vascular or immunologic phenomena. As
the initial risk of IE in SAB patients is high and the symptoms is
unspecific TTE and TEE is recommended in the assessment of
SAB patients in general. However, the present study indicate that
high-quality TTE might be sufficient in SAB patients with no
additional risk factors or clinical evidence of IE, but the threshold
for additional TEE should be low. A third key finding was that
the prevalence of IE in SAB patients admitted at Main Regional
Hospitals and Tertiary Cardiac Hospitals was comparable indicat-
ing that this is a widespread problem, which is not isolated to Ter-
tiary Cardiac Hospitals.
Collectively, our data provides compelling evidence that all
patients with SAB should undergo echocardiographic screening
in order to minimize the risk of missing this potentially lethal
diagnosis.
The current investigation has several limitations. The study is
susceptible to selection bias as not all of the eligible SAB patients
were included. Therefore, it is possible that only high-risk patients
were selected for echocardiography, especially as none of the eli-
gible patients not referred for echocardiography were diagnosed
with IE. However, it is likely that unrecognized IE patients in this
population either were cured by antibiotic treatment due to a
short duration of the disease, were readmitted with recurrent
SAB infection, or died due to endocarditis, explaining the high
mortality in this population. Accordingly, the prevalence reported
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Symptoms and clinical findings in
Staphylococcus aureus bacteraemia patients with and
without definite infective endocarditis
SAB patients
without IE
(n 5 191), No.
(%)
SAB patients
with IE
(n5 53), No.
(%)
P-value
Symptoms
Headache 36 (19) 10 (19) 1.0
Fatigue 68 (36) 25 (47) 0.1
Nausea 50 (26) 14 (26) 1.0
Muscle aches 57 (30) 14 (26) 0.6
Weight loss 10 (5) 2 (4) 1.0
Dyspnea 49 (26) 17 (32) 0.4
Edema 20 (10) 6 (11) 0.9
Clinical findings
Heart failure,
right sided
13 (7) 7 (13) 0.2
Heart failure, left
sided
10 (5) 7 (13) 0.06
Heart murmur 30 (16) 23 (43) ,0.001
Vascular or
immunologic
phenomenaa
1 (1) 6 (11) ,0.001
Embolic events 6 (3) 13 (25) ,0.001
Neurological
impairment
48 (25) 20 (38) 0.07
Septic shock 67 (35) 26 (49) 0.06
aJaneway lesion, conjunctival haemorrhage, petechiae, splinters.
R.V. Rasmussen et al.418
by guest on January 16, 2017
D
ow
nloaded from
 
in the present study has to be a conservative estimate of the ‘true’
IE prevalence. To minimize selection bias, the current study was
designed as a multicentre study including patients from both
Main Regional Hospitals and Tertiary Cardiac Hospitals and the
inclusion rate (73%) is to our knowledge the highest yet to be
reported. Furthermore, we were able to keep track on patients
not included in our study allowing us to follow-up on all eligible
patients. Another concern is the possibility that the prevalence
reported in the current study is underestimated as 38% of the
patients were examined with TTE without an additional TEE.
However, as the quality and resolution of TTE continues to
improve the ability of TTE to detect vegetations has become
better especially in patients with native valve IE. For example, a
recent study by Casella et al.20 reported that the sensitivity of
TTE for diagnosing native valve IE was 82%, and almost 90% in
patients with good image quality. Another concern is that as the
quality of the images provided by echocardiography continues to
improve smaller mobile structures are seen and the interpretation
of significant vs. non-significant, i.e. degenerative echocardiographic
findings becomes more difficult with the risk of false-positive
results, which may result in inappropriate diagnosis of IE. To
reduce the risk of false-positive cases in the present study only
cases of definite IE, according to the modified Duke criteria,
were included.
Conclusion
SAB is associated with a high prevalence of IE if screening with
echocardiography is performed as a routine examination in a
roughly unselected population. Risk stratification based on clinical
data alone may result in inappropriate classification in a smaller
number of patients with the risk of unrecognized cases of IE. As
S. aureus IE is a life-threatening disease associated with a high
rate of complications and a high mortality a dedicated effort is
needed in the evaluation of SAB patients including a better diag-
nostic setup with widespread use of echocardiographic screening
as recommended by international guidelines.
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Advanced right lung adenocarcinoma invading left atrium and left ventricle
via right superior pulmonary vein and partially occluding mitral valve
in diastole
Mehmood A. Jadoon1* and Pushpinder Sidhu2
1Royal Victoria Hospital, Belfast, UK and 2Cardiothoracic Unit, Old Corridor, Royal Victoria Hospital, 274 Grosvenor Road, Belfast BT12 6BA, UK
* Corresponding author: 5 Orange Hall Lane, Lisburn, County Antrim BT28 2UL, UK. Tel: +44 28 92 583 419, Email: mehmood01@hotmail.com
We present a challenging yet interesting case of a 51-year-old lady who
presented with dry cough and night sweats. Computed tomographic
(CT) scan showed an advanced tumour of right upper lobe of the
lung invading heart. Transoesophageal echocardiography confirmed a
tumour tracking via right superior pulmonary vein into left atrium and
then through mitral valve in diastole into left ventricle partially occluding
mitral valve. Transoesophageal echocardiography ruled out any attach-
ment of the tumour to any part of heart. There was no evidence of
any distant metastasis on positron emission tomographic scan.
Patient underwent excision of left atrial extension of tumour on
bypass via median sternotomy. Immediately afterwards right pneumo-
nectomy was performed via posterolateral thoracotomy. This tumour
was moderately differentiated adenocarcinoma and it was staged
pT4N2 (Stage 3b) (6th Edition of the AJCC).
Post-operatively she received four cycles of cisplatin- and vinorelbine-based chemotherapy. A year and half after her operation
patient is doing very well. A follow-up CT scan at 18 months post-operatively shows no signs of any recurrent disease or distant
metastasis.
Conclusion
We conclude that if carefully evaluated in selected patients with lung tumours having polypoidal extension into the left atrium and left
ventricle with no attachment or invasion of endocardium or heart valves need not be considered an absolute contraindication to sur-
gical resection. In fact, in highly selected patients, pneumonectomy with retrieval of tumour from left atrium on bypass can provide
excellent control of the disease, and even may lead to a definitive cure.
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